Patients with disseminated recurrences with metastatic disease were managed with the standard systemic treatment available at the institution, Pazopanib, which is a multi‐target tyrosine kinase inhibitor of vascular endothelial growth factor receptors 1, 2 and 3 (VEGFR‐1, VEGFR‐2, VEGFR‐3), platelet‐derived growth factors α and β (PDGFR‐α and PDGFR‐β) and stem cell factor receptor (c‐KIT). Here, FLT4 is linked to metastatic neoplasm.